import { createClient } from '@supabase/supabase-js';
import { readFileSync } from 'fs';
import { dirname, join } from 'path';
import { fileURLToPath } from 'url';

const __dirname = dirname(fileURLToPath(import.meta.url));
function loadEnv() {
  const envContent = readFileSync(join(__dirname, '../.env.local'), 'utf8');
  const envVars = {};
  envContent.split('\n').forEach(line => {
    const match = line.match(/^([^=]+)=(.*)$/);
    if (match) {
      let value = match[2].trim();
      if ((value.startsWith('"') && value.endsWith('"')) || (value.startsWith("'") && value.endsWith("'"))) value = value.slice(1, -1);
      envVars[match[1].trim()] = value;
    }
  });
  return envVars;
}
const env = loadEnv();
const supabase = createClient(env.NEXT_PUBLIC_SUPABASE_URL, env.SUPABASE_SERVICE_ROLE_KEY);

const content = `## Quick Answer

**MAGL (monoacylglycerol lipase)** is the enzyme responsible for breaking down [2-AG](/glossary/2-ag), the most abundant [endocannabinoid](/glossary/endocannabinoid) in the brain. While [FAAH](/glossary/faah-enzyme) degrades [anandamide](/glossary/anandamide), MAGL handles 2-AG—making these two enzymes the primary regulators of [endocannabinoid tone](/glossary/endocannabinoid-tone). MAGL inhibition is being researched for pain, inflammation, and neuroprotection.

---

## What Is MAGL?

MAGL (also written as MGL or MGLL) is a serine hydrolase enzyme that terminates 2-AG signaling by breaking it down into arachidonic acid and glycerol.

### MAGL Quick Facts

| Property | Detail |
|----------|--------|
| **Full name** | Monoacylglycerol lipase |
| **Gene** | MGLL |
| **Primary substrate** | [2-AG](/glossary/2-ag) (2-arachidonoylglycerol) |
| **Location** | Brain, liver, adipose tissue |
| **Function** | Degrades 2-AG, terminates signaling |
| **Comparison** | MAGL is to 2-AG as FAAH is to anandamide |

---

## How MAGL Works

### The 2-AG Lifecycle

| Stage | Process |
|-------|---------|
| **1. Synthesis** | 2-AG made on demand from membrane lipids |
| **2. Release** | 2-AG released at synapse |
| **3. Signaling** | 2-AG activates [CB1](/glossary/cb1-receptor)/[CB2](/glossary/cb2-receptor) receptors |
| **4. Degradation** | MAGL breaks down 2-AG |
| **5. Products** | Arachidonic acid + glycerol |

### MAGL's Enzymatic Reaction

| Substrate | Products | Significance |
|-----------|----------|--------------|
| **2-AG** | Arachidonic acid + glycerol | Ends 2-AG signaling |

### Arachidonic Acid Connection

MAGL's breakdown of 2-AG produces arachidonic acid, which:

| Arachidonic Acid Fate | Effect |
|----------------------|--------|
| **Prostaglandin synthesis** | Inflammatory mediators |
| **Leukotriene synthesis** | Inflammatory cascade |
| **Membrane reincorporation** | Recycled into lipids |

**Key insight:** MAGL inhibition reduces inflammation partly by limiting arachidonic acid supply.

---

## MAGL vs. FAAH

### The Two Key Degradation Enzymes

| Property | MAGL | [FAAH](/glossary/faah-enzyme) |
|----------|------|------|
| **Primary target** | 2-AG | Anandamide |
| **Location** | Presynaptic (mostly) | Postsynaptic |
| **Brain 2-AG role** | ~85% of degradation | Minor |
| **Inhibition effect** | Raises 2-AG | Raises anandamide |
| **Drug development** | Active research | Clinical trials |

### Why Both Matter

| System | Role |
|--------|------|
| **Pain** | Both endocannabinoids reduce pain |
| **Anxiety** | Different effects (anandamide more anxiolytic) |
| **Inflammation** | 2-AG/MAGL pathway more prominent |
| **[ECS](/glossary/endocannabinoid-system) tone** | Both contribute to baseline signaling |

---

## MAGL Inhibition Research

### Therapeutic Potential

| Condition | Rationale | Evidence |
|-----------|-----------|----------|
| **Chronic pain** | Enhanced 2-AG signaling | Preclinical |
| **Neuroinflammation** | Reduced arachidonic acid | Preclinical |
| **Anxiety** | Enhanced [ECS](/glossary/endocannabinoid-system) tone | Preclinical |
| **Neuroprotection** | Multiple mechanisms | Preclinical |
| **Cancer** | Anti-proliferative effects | Early research |

### Pain Research

| Finding | Context |
|---------|---------|
| **Acute pain** | MAGL inhibitors reduce pain responses |
| **Neuropathic pain** | Enhanced 2-AG helps chronic pain |
| **Inflammatory pain** | Dual mechanism (CB + anti-inflammatory) |
| **vs. direct CB agonists** | May have fewer side effects |

### Inflammation Research

| Mechanism | Effect |
|-----------|--------|
| **Less arachidonic acid** | Fewer prostaglandins |
| **More 2-AG** | Enhanced CB2 anti-inflammatory signaling |
| **Neuroinflammation** | Protective in brain injury models |

---

## MAGL Inhibitors

### Research Compounds

| Compound | Type | Notes |
|----------|------|-------|
| **JZL184** | Selective MAGL inhibitor | Most studied research tool |
| **KML29** | Selective MAGL inhibitor | Improved selectivity |
| **MJN110** | Potent MAGL inhibitor | Research compound |
| **ABX-1431** | Clinical candidate | Has entered human trials |

### Natural MAGL Modulators

| Compound | Source | Evidence |
|----------|--------|----------|
| **CBD** | Cannabis | Weak MAGL interaction (controversial) |
| **Pristimerin** | Celastrus plants | MAGL inhibition shown |

---

## MAGL and the Brain

### Distribution

| Brain Region | MAGL Presence | Significance |
|--------------|---------------|--------------|
| **Hippocampus** | High | Memory, learning |
| **Cerebellum** | High | Motor control |
| **Cortex** | Moderate | Cognition |
| **Amygdala** | Moderate | Emotional processing |

### Presynaptic Location

| Feature | Implication |
|---------|-------------|
| **MAGL on presynaptic neuron** | Controls retrograde signaling duration |
| **FAAH postsynaptic** | Different regulatory role |
| **Spatial separation** | Precise signaling control |

---

## Challenges in MAGL Drug Development

### Tolerance Concerns

| Issue | Detail |
|-------|--------|
| **Chronic inhibition** | May cause CB1 receptor desensitization |
| **Long-term effects** | Tolerance observed in animal studies |
| **vs. FAAH inhibition** | FAAH inhibitors show less tolerance |

### Selectivity

| Concern | Context |
|---------|---------|
| **Other substrates** | MAGL has additional lipid substrates |
| **Off-target effects** | Some inhibitors lack selectivity |
| **Arachidonic acid reduction** | May affect other pathways |

---

## MAGL in Disease States

### Altered MAGL Activity

| Condition | MAGL Change | Implication |
|-----------|-------------|-------------|
| **Alzheimers disease** | Elevated MAGL | Reduced 2-AG tone |
| **Multiple sclerosis** | Altered expression | ECS dysfunction |
| **Cancer** | Often elevated | May promote growth |
| **Chronic stress** | Variable changes | ECS disruption |

### [Clinical Endocannabinoid Deficiency](/articles/endocannabinoid-deficiency)

| Factor | Role |
|--------|------|
| **Excessive MAGL** | Could contribute to low 2-AG |
| **MAGL inhibition** | Potential therapeutic approach |
| **Combined with FAAH** | Dual inhibition strategies |

---

## Related Articles

- [What Is 2-AG?](/articles/2-ag-endocannabinoid) - MAGLs primary substrate
- [What Is FAAH?](/articles/faah-enzyme) - The anandamide-degrading enzyme
- [The Endocannabinoid System](/articles/endocannabinoid-system) - Complete ECS overview
- [Clinical Endocannabinoid Deficiency](/articles/endocannabinoid-deficiency) - When the ECS is underactive

---

## Frequently Asked Questions

### What does MAGL do?

MAGL is the enzyme that breaks down 2-AG, the most abundant endocannabinoid in the brain. By degrading 2-AG, MAGL controls how long endocannabinoid signaling lasts. Its activity helps maintain [endocannabinoid tone](/glossary/endocannabinoid-tone).

### How is MAGL different from FAAH?

[FAAH](/glossary/faah-enzyme) primarily breaks down [anandamide](/glossary/anandamide), while MAGL breaks down [2-AG](/glossary/2-ag). They're located in different parts of the synapse and affect different aspects of endocannabinoid signaling. Both are drug development targets.

### Does CBD affect MAGL?

CBD's interaction with MAGL is minimal and controversial. CBD primarily affects [FAAH](/glossary/faah-enzyme) (preserving anandamide), not MAGL. Some studies suggest very weak MAGL effects, but this isn't considered a primary CBD mechanism.

### Are there MAGL inhibitor drugs?

No MAGL inhibitors are currently approved for medical use. ABX-1431 has entered human clinical trials. Research compounds like JZL184 are used in laboratories to study MAGL's role in various conditions.

### Why is MAGL important for inflammation?

When MAGL breaks down 2-AG, it produces arachidonic acid—the precursor to inflammatory prostaglandins. Inhibiting MAGL reduces arachidonic acid availability and enhances anti-inflammatory 2-AG signaling, providing dual anti-inflammatory effects.

---

*Medical Disclaimer: This article is for educational purposes only. MAGL inhibitors are not approved medications. This information describes research findings, not treatment recommendations.*

---

### References

1. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol*. 2007;14(12):1347-1356.

2. Nomura DK, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *Science*. 2011;334(6057):809-813.

3. Mulvihill MM, Bhutta ZA, Bhutta AT. Monoacylglycerol Lipase (MAGL) as a Promising Drug Target. *Life Sci*. 2019;238:116874.

4. Piro JR, et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimers disease. *Cell Rep*. 2012;1(6):617-623.`;

async function main() {
  const { data: category } = await supabase.from('kb_categories').select('id').eq('slug', 'science').single();
  if (!category) return;
  const { data, error } = await supabase.from('kb_articles').insert({
    title: 'What Is MAGL? The 2-AG Degrading Enzyme',
    slug: 'magl-enzyme',
    excerpt: 'Learn about MAGL (monoacylglycerol lipase)—the enzyme that breaks down 2-AG, the most abundant endocannabinoid. Understand its role in pain, inflammation, and ECS tone.',
    content: content,
    status: 'published',
    featured: false,
    article_type: 'science',
    category_id: category.id,
    reading_time: 9,
    meta_title: 'What Is MAGL? The 2-AG Degrading Enzyme Explained',
    meta_description: 'Understand MAGL, the enzyme that degrades 2-AG. Learn how it complements FAAH, its role in inflammation, and research into MAGL inhibitors.',
    language: 'en',
    published_at: new Date().toISOString()
  }).select().single();
  if (error) console.error('Error:', error);
  else console.log('MAGL Enzyme article inserted:', data.slug);
}
main();
